Cowen and Company reaffirmed their buy rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a research note released on Wednesday. Cowen and Company currently has a $112.00 price objective on the biopharmaceutical company’s stock.
Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company reaffirmed an outperform rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Jefferies Group LLC started coverage on Intercept Pharmaceuticals in a research report on Monday, July 10th. They issued a buy rating and a $275.00 price objective on the stock. Cantor Fitzgerald reaffirmed an underweight rating and issued a $69.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Bank of America Corporation lowered their price objective on Intercept Pharmaceuticals from $102.00 to $73.00 and set an underperform rating on the stock in a research report on Friday, October 13th. Finally, Robert W. Baird reaffirmed an outperform rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals has an average rating of Hold and an average target price of $153.76.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.48) by $0.59. The business had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm’s quarterly revenue was up 697.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.59) EPS.
COPYRIGHT VIOLATION NOTICE: “Intercept Pharmaceuticals’ (ICPT) “Buy” Rating Reaffirmed at Cowen and Company” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/02/intercept-pharmaceuticals-icpt-buy-rating-reaffirmed-at-cowen-and-company.html.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO David Shapiro sold 1,250 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the sale, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. Insiders sold a total of 4,069 shares of company stock valued at $325,974 in the last quarter. 9.20% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. WFG Advisors LP increased its stake in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares in the last quarter. IFP Advisors Inc increased its stake in Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 730 shares in the last quarter. Aperio Group LLC purchased a new stake in Intercept Pharmaceuticals in the 2nd quarter worth $212,000. SG Americas Securities LLC purchased a new stake in Intercept Pharmaceuticals in the 2nd quarter worth $235,000. Finally, QCM Cayman Ltd. purchased a new stake in Intercept Pharmaceuticals in the 2nd quarter worth $237,000. Institutional investors and hedge funds own 82.81% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.